vs
Side-by-side financial comparison of CORCEPT THERAPEUTICS INC (CORT) and DouYu International Holdings Ltd (DOYU). Click either name above to swap in a different company.
CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $147.1M, roughly 1.4× DouYu International Holdings Ltd).
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
DouYu International Holdings Ltd operates a leading live streaming platform centered on video game and esports content primarily in mainland China. It offers interactive live streams covering professional esports tournaments, casual gaming content, and variety entertainment, targeting young gaming enthusiasts as its core user base, with main revenue streams including virtual gifting, advertising, and paid memberships.
CORT vs DOYU — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $202.1M | $147.1M |
| Net Profit | $24.3M | — |
| Gross Margin | 98.7% | 13.5% |
| Operating Margin | 2.2% | — |
| Net Margin | 12.0% | — |
| Revenue YoY | 11.1% | — |
| Net Profit YoY | -21.0% | — |
| EPS (diluted) | $0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $202.1M | — | ||
| Q3 25 | $207.6M | — | ||
| Q2 25 | $194.4M | $147.1M | ||
| Q1 25 | $157.2M | $130.5M | ||
| Q4 24 | $181.9M | — | ||
| Q3 24 | $182.5M | — | ||
| Q2 24 | $163.8M | $142.0M | ||
| Q1 24 | $146.8M | $144.0M |
| Q4 25 | $24.3M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $35.1M | — | ||
| Q1 25 | $20.5M | $-11.0M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $47.2M | — | ||
| Q2 24 | $35.5M | $-6.8M | ||
| Q1 24 | $27.8M | $-12.2M |
| Q4 25 | 98.7% | — | ||
| Q3 25 | 97.8% | — | ||
| Q2 25 | 98.2% | 13.5% | ||
| Q1 25 | 98.5% | 12.0% | ||
| Q4 24 | 98.4% | — | ||
| Q3 24 | 98.4% | — | ||
| Q2 24 | 98.5% | 8.2% | ||
| Q1 24 | 98.3% | 10.5% |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 2.2% | -2.8% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 25.5% | — | ||
| Q2 24 | 21.7% | -11.6% | ||
| Q1 24 | 20.1% | -16.1% |
| Q4 25 | 12.0% | — | ||
| Q3 25 | 9.5% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 13.1% | -8.4% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 25.9% | — | ||
| Q2 24 | 21.7% | -4.8% | ||
| Q1 24 | 18.9% | -8.5% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.16 | — | ||
| Q2 25 | $0.29 | — | ||
| Q1 25 | $0.17 | — | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $0.32 | — | ||
| Q1 24 | $0.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $372.2M | $214.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $647.8M | $279.9M |
| Total Assets | $836.7M | $448.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $372.2M | — | ||
| Q3 25 | $421.7M | — | ||
| Q2 25 | $342.2M | $214.4M | ||
| Q1 25 | $322.8M | $35.2M | ||
| Q4 24 | $383.3M | — | ||
| Q3 24 | $380.3M | — | ||
| Q2 24 | $473.2M | $558.8M | ||
| Q1 24 | $410.8M | $70.7M |
| Q4 25 | $647.8M | — | ||
| Q3 25 | $631.9M | — | ||
| Q2 25 | $635.8M | $279.9M | ||
| Q1 25 | $683.3M | $37.4M | ||
| Q4 24 | $679.6M | — | ||
| Q3 24 | $638.8M | — | ||
| Q2 24 | $596.2M | $895.6M | ||
| Q1 24 | $547.9M | $126.4M |
| Q4 25 | $836.7M | — | ||
| Q3 25 | $823.6M | — | ||
| Q2 25 | $801.7M | $448.1M | ||
| Q1 25 | $846.5M | $60.8M | ||
| Q4 24 | $840.6M | — | ||
| Q3 24 | $784.3M | — | ||
| Q2 24 | $714.6M | $1.1B | ||
| Q1 24 | $655.9M | $156.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.4M | — |
| Free Cash FlowOCF − Capex | $38.4M | — |
| FCF MarginFCF / Revenue | 19.0% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.58× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.4M | — | ||
| Q3 25 | $54.5M | — | ||
| Q2 25 | $43.9M | — | ||
| Q1 25 | $5.1M | — | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $73.8M | — | ||
| Q2 24 | $41.2M | — | ||
| Q1 24 | $23.8M | — |
| Q4 25 | $38.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $43.9M | — | ||
| Q1 25 | $5.0M | — | ||
| Q4 24 | $59.2M | — | ||
| Q3 24 | $72.2M | — | ||
| Q2 24 | $40.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 3.2% | — | ||
| Q4 24 | 32.5% | — | ||
| Q3 24 | 39.5% | — | ||
| Q2 24 | 24.9% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 1.93× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
